JP2016511407A - 非高比重リポタンパク質由来ｃｖｄマーカー - Google Patents

非高比重リポタンパク質由来ｃｖｄマーカー Download PDF

Info

Publication number
JP2016511407A
JP2016511407A JP2015560715A JP2015560715A JP2016511407A JP 2016511407 A JP2016511407 A JP 2016511407A JP 2015560715 A JP2015560715 A JP 2015560715A JP 2015560715 A JP2015560715 A JP 2015560715A JP 2016511407 A JP2016511407 A JP 2016511407A
Authority
JP
Japan
Prior art keywords
lipid
subject
tag
concentration ratio
cvd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015560715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511407A5 (cg-RX-API-DMAC7.html
Inventor
レイヨ ラークソネン
レイヨ ラークソネン
Original Assignee
ゾラ バイオサイエンシーズ オサケ ユキチュア
ゾラ バイオサイエンシーズ オサケ ユキチュア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾラ バイオサイエンシーズ オサケ ユキチュア, ゾラ バイオサイエンシーズ オサケ ユキチュア filed Critical ゾラ バイオサイエンシーズ オサケ ユキチュア
Publication of JP2016511407A publication Critical patent/JP2016511407A/ja
Publication of JP2016511407A5 publication Critical patent/JP2016511407A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/02—Triacylglycerols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
JP2015560715A 2013-03-08 2014-03-07 非高比重リポタンパク質由来ｃｖｄマーカー Pending JP2016511407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775445P 2013-03-08 2013-03-08
US61/775,445 2013-03-08
PCT/EP2014/054499 WO2014135696A1 (en) 2013-03-08 2014-03-07 Non-high density lipoprotein derived cvd markers

Publications (2)

Publication Number Publication Date
JP2016511407A true JP2016511407A (ja) 2016-04-14
JP2016511407A5 JP2016511407A5 (cg-RX-API-DMAC7.html) 2017-04-13

Family

ID=50236206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560715A Pending JP2016511407A (ja) 2013-03-08 2014-03-07 非高比重リポタンパク質由来ｃｖｄマーカー

Country Status (6)

Country Link
US (1) US20160018423A1 (cg-RX-API-DMAC7.html)
EP (1) EP2965092A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016511407A (cg-RX-API-DMAC7.html)
CN (1) CN105008931A (cg-RX-API-DMAC7.html)
CA (1) CA2903946A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014135696A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508322A (ja) * 2018-12-06 2022-01-19 ゾラ バイオサイエンシーズ オサケ ユキチュア 心血管イベントに対するバイオマーカー

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
HUE056203T2 (hu) * 2015-01-09 2022-01-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására
CN105748469B (zh) * 2016-02-24 2019-07-23 长沙佰顺生物科技有限公司 一种安塞曲匹辛伐他汀药物组合物
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CN112630344B (zh) * 2020-12-08 2021-12-14 河北医科大学第二医院 代谢标志物在脑梗死中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508519A (ja) * 1997-12-17 2002-03-19 ハインリッヒ・ヴィーラント リポ蛋白質に含有されるトリグリセリドの測定のための手続および診断用製品
JP2004083465A (ja) * 2001-02-23 2004-03-18 Biofrontera Pharmaceuticals Gmbh Ｓｍアーゼインヒビターとしてのシホスタチンアナログ
JP2005503110A (ja) * 2001-01-02 2005-02-03 ザ・クリーブランド・クリニック・ファンデーション ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子
JP2010065040A (ja) * 1997-08-05 2010-03-25 Trustees Of Columbia Univ In The City Of New York 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法
WO2011161062A2 (en) * 2010-06-20 2011-12-29 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057081A1 (en) * 2004-11-24 2006-06-01 Mitsuyo Okazaki Method for analyzing lipoproteins
AU2008219700B2 (en) * 2007-02-22 2014-05-29 Health Diagnostic Laboratory, Inc. Metabolic markers of diabetic conditions and methods of use thereof
WO2011063470A1 (en) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010065040A (ja) * 1997-08-05 2010-03-25 Trustees Of Columbia Univ In The City Of New York 後生的グリケーション最終生成物の可溶性レセプター（ｓＲＡＧＥ）を用いて加速性アテローム性動脈硬化症を予防する方法
JP2002508519A (ja) * 1997-12-17 2002-03-19 ハインリッヒ・ヴィーラント リポ蛋白質に含有されるトリグリセリドの測定のための手続および診断用製品
JP2005503110A (ja) * 2001-01-02 2005-02-03 ザ・クリーブランド・クリニック・ファンデーション ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子
JP2004083465A (ja) * 2001-02-23 2004-03-18 Biofrontera Pharmaceuticals Gmbh Ｓｍアーゼインヒビターとしてのシホスタチンアナログ
WO2011161062A2 (en) * 2010-06-20 2011-12-29 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TALL, AR ET AL., J. CLIN. INVEST., vol. 62, JPN6018008686, December 1978 (1978-12-01), pages 1354 - 1363, ISSN: 0003755443 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508322A (ja) * 2018-12-06 2022-01-19 ゾラ バイオサイエンシーズ オサケ ユキチュア 心血管イベントに対するバイオマーカー
US12399188B2 (en) 2018-12-06 2025-08-26 Zora Biosciences Oy Biomarkers for cardiovascular events

Also Published As

Publication number Publication date
EP2965092A1 (en) 2016-01-13
WO2014135696A1 (en) 2014-09-12
CN105008931A (zh) 2015-10-28
US20160018423A1 (en) 2016-01-21
CA2903946A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US20240385201A1 (en) Lipidomic biomarkers for atherosclerosis and cardiovascular disease
JP6605521B2 (ja) 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー
JP6388284B2 (ja) スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
JP6388283B2 (ja) スタチン治療を受けていない冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
JP5980900B2 (ja) スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
JP2016511407A (ja) 非高比重リポタンパク質由来ｃｖｄマーカー
JP2016191718A (ja) スタチン誘発性筋毒性の高感度検出のためのバイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181112